New Advances in the Treatment of Adult Chronic Immune Thrombocytopenic Purpura: Role of Thrombopoietin Receptor-stimulating Agents

Overview

Journal Biologics

Date 2010 Jan 8

PMID 20054440

Citations 1

Authors

Ara Metjian

Charles S Abrams

Affiliations

Soon will be listed here.

Abstract

Decades of basic science and clinical research have led to an increased understanding of the pathophysiology of immune thrombocytopenic purpura (ITP), the processes underlying thrombopoiesis, and the treatment of chronic ITP. Now, new agents are available to treat ITP in a nonimmunosuppressive fashion. Lessons learned from the clinical trials of recombinant human thrombopoietin (TPO) have led to the development of a novel class of compounds: nonimmunogenic agonists of the thrombopoietin receptor. Representing the first nonimmunosuppressive agents to treat chronic refractory ITP in decades, medications such as romiplostim and eltrombopag were recently approved by the US Food and Drug Administration. These new agents offer physicians a new tool for treating difficult cases of ITP in their medical armamentarium. Additional TPO mimetics are also being developed that show promise in vitro, and await future development.

Citing Articles

Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions.

La M, Sedykh A, Fourches D, Muratov E, Tropsha A Drug Saf. 2018; 41(11):1059-1072.

PMID: 29876834 PMC: 6212308. DOI: 10.1007/s40264-018-0688-5.

References

Alexander W, Metcalf D, Dunn A . Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995; 14(22):5569-78. PMC: 394671. DOI: 10.1002/j.1460-2075.1995.tb00244.x. View

Gurney A, Wong S, Henzel W, de Sauvage F . Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A. 1995; 92(12):5292-6. PMC: 41680. DOI: 10.1073/pnas.92.12.5292. View

Wendling F, Varlet P, Charon M, Tambourin P . MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology. 1986; 149(2):242-6. DOI: 10.1016/0042-6822(86)90125-x. View

Hunt P, Li Y, Nichol J, Hokom M, Bogenberger J, Swift S . Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood. 1995; 86(2):540-7. View

Bussel J, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L . Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9664):641-8. DOI: 10.1016/S0140-6736(09)60402-5. View

De Gabriele G, Penington D . Regulation of platelet production: "thrombopoietin". Br J Haematol. 1967; 13(2):210-5. DOI: 10.1111/j.1365-2141.1967.tb08733.x. View

Ulich T, Del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S . Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996; 87(12):5006-15. View

Kaushansky K, Lok S, Holly R, Broudy V, Lin N, BAILEY M . Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994; 369(6481):568-71. DOI: 10.1038/369568a0. View

Yamada M, Komatsu N, Okada K, Kato T, Miyazaki H, Miura Y . Thrombopoietin induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in a human thrombopoietin-dependent cell line. Biochem Biophys Res Commun. 1995; 217(1):230-7. DOI: 10.1006/bbrc.1995.2768. View

10.

Gurney A, de Sauvage F, Moore M . Thrombocytopenia in c-mpl-deficient mice. Science. 1994; 265(5177):1445-7. DOI: 10.1126/science.8073287. View

11.

Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R . Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-8. DOI: 10.7326/0003-4819-132-5-200003070-00005. View

12.

Rice L . Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Investig Drugs. 2006; 7(9):834-41. View

13.

Le Coniat M, Souyri M, Vigon I, Wendling F, Tambourin P, Berger R . The human homolog of the myeloproliferative virus maps to chromosome band 1p34. Hum Genet. 1989; 83(2):194-6. DOI: 10.1007/BF00286717. View

14.

Lok S, Kaushansky K, Holly R, Kuijper J, Oort P, Grant F . Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994; 369(6481):565-8. DOI: 10.1038/369565a0. View

15.

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

16.

Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T . Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007; 47(12):1489-97. DOI: 10.1177/0091270007306563. View

17.

Dahlen D, Broudy V, Drachman J . Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood. 2003; 102(1):102-8. DOI: 10.1182/blood-2002-11-3468. View

18.

Cole J, Marzec U, Gunthel C, Karpatkin S, Worford L, Sundell I . Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood. 1998; 91(9):3239-46. View

19.

Broudy V, Lin N . AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2003; 25(2):52-60. DOI: 10.1016/j.cyto.2003.05.001. View

20.

Vigon I, Mornon J, Cocault L, Mitjavila M, Tambourin P, Gisselbrecht S . Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992; 89(12):5640-4. PMC: 49348. DOI: 10.1073/pnas.89.12.5640. View